FrançaisAre analysts right about Roivant Sciences (ROIV)?
📈 See the interactive version (live chart) →
Historical analyst accuracy
For Roivant Sciences, we replayed every analyst price target of the past 12 months and measured the real outcome: 55% were profitable, average return +45% (69 calls). At 3 months: +9% average return (54% profitable). The higher the %, the more often analysts were right on this stock.
Most reliable analysts on this stock (past track record)
Their past track record on this stock (targets replayed against real prices) — not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| HC Wainwright & Co. | 21 | 57% | +50% |
| Cantor Fitzgerald | 9 | 22% | +22% |
| JP Morgan | 7 | 86% | +51% |
| Goldman Sachs | 6 | 50% | +44% |
| Truist Securities | 5 | 20% | -7% |
Frequently asked questions
Is Roivant Sciences a buy right now?
The analyst consensus on Roivant Sciences (ROIV) is "Buy" (23 bullish, 0 bearish calls over 12 months). This is not advice: historically, 55% of their targets on this stock turned out profitable over 1 year.
What is Roivant Sciences's price target?
The median 12-month price target is $51.50 (+37% vs $37.52), ranging from $46.00 to $56.00 (6 analysts).
Are analysts accurate on Roivant Sciences?
Over 1 year, 55% of analyst targets on Roivant Sciences were profitable, for an average return of +45% (across 69 timestamped calls). This is JPI Invest's accuracy metric.
What is the Roivant Sciences stock forecast?
Analysts target a median of $51.50 within 12 months, i.e. +37% vs the current price. The most bullish targets $56.00, the most cautious $46.00.
What is the Roivant Sciences stock forecast for 2026 or long term (2030)?
Note: analyst targets are 12-month (median $51.50, +37%), NOT 2030. No reliable 5-10 year price forecast exists (« 2030 prediction » models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (55%), and the stock's past trajectory.
Is Roivant Sciences overvalued?
Detailed valuation data for Roivant Sciences is available in the interactive analysis.
📊 See the full interactive analysis of Roivant Sciences →
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.